Coherus closes $50.1 million public offering of common stock
Coherus Oncology, Inc. successfully closed a public offering, raising approximately $50.1 million through the sale of 28.6 million shares at $1.75 each. The proceeds will fund the commercialization of LOQTORZI, clinical development, and general corporate purposes, as the company transitions from a biosimilar firm to a clinical-stage oncology biotech. Despite recent stock volatility and anticipated sales decline by analysts, Coherus has significantly reduced its debt and shows strong price momentum over the last six months.
Oncology biotech Coherus raises $50M for LOQTORZI and clinical programs
Coherus Oncology (NASDAQ: CHRS) has closed an underwritten public offering of 28.6 million common shares at $1.75 per share, generating approximately $50.1 million in gross proceeds. The company plans to use these funds to support the commercialization of its PD-1 inhibitor LOQTORZI, advance its clinical development programs, and for general corporate purposes. This financing was led by healthcare-dedicated investors including Janus Henderson Investors, HBM Healthcare Investments, and Samsara BioCapital.
Coherus Oncology, Inc. (NASDAQ:CHRS) Given Average Rating of "Hold" by Analysts
Coherus Oncology, Inc. (NASDAQ:CHRS) has received an average "Hold" rating from analysts, with a 12-month average price target of $5.5125. Recent analyst actions include Oppenheimer initiating coverage with an "outperform" rating and a $10.00 price target, alongside a recent upgrade from "sell" to "hold" by Wall Street Zen. The company's stock has recently traded down 19.9% and institutional investors hold 72.82% of its shares.
Coherus Oncology prices stock offering to raise $50.1M
Coherus BioSciences announced the pricing of an underwritten public offering of 33.4 million shares of its common stock at $1.50 per share, aiming to raise $50.1 million before underwriting discounts and commissions. The offering also includes warrants to purchase up to 33.4 million additional shares. This financial move is expected to close around February 20, 2026, and is subject to standard closing conditions.
Coherus BioSciences stock falls after pricing $50.1 million share offering
Coherus BioSciences Inc. (NASDAQ:CHRS) stock tumbled 14.5% in premarket trading after announcing the pricing of a public offering for 28.6 million shares at $1.75 each, a significant discount to its previous closing price. The offering is expected to raise $50.1 million in gross proceeds, intended to support the commercialization of its oncology treatment LOQTORZI, advance product candidate development, and for general corporate purposes. The offering is anticipated to close around February 17, 2026.
Coherus BioSciences Prices $50.1 Million Share Offering
Coherus BioSciences announced the pricing of a $50.1 million share offering. The company is a commercial-stage biopharmaceutical firm focused on developing cancer immunotherapies, with a pipeline including several antibody immunotherapy candidates.
Coherus Oncology prices $50.1 million public offering of common stock
Coherus Oncology has priced an underwritten public offering of 28.6 million shares of common stock at $1.75 per share, aiming to generate approximately $50.1 million in gross proceeds. The company plans to use these proceeds for the commercialization of LOQTORZI, continued clinical development of product candidates, and general corporate purposes. This follows other recent news, including a clinical supply agreement with Johnson & Johnson and Oppenheimer reiterating an Outperform rating on Coherus stock.
Coherus Oncology Prices Public Offering at $1.75 per Share
Coherus Oncology announced a public offering of 28.6 million shares at $1.75 each, aiming to raise approximately $50.1 million. The proceeds will fund the commercialization of LOQTORZI®, continued clinical development, and general corporate purposes. Underwriters TD Cowen, Guggenheim Securities, and Oppenheimer & Co. have a 30-day option to purchase an additional 4.29 million shares.
Coherus Oncology, Inc. Announces Pricing of Public Offering of Common Stock
Coherus Oncology, Inc. (NASDAQ: CHRS) has announced the pricing of an underwritten public offering of 28,600,000 shares of its common stock at $1.75 per share, aiming to raise approximately $50.1 million before underwriting discounts. The company plans to use the net proceeds to support the commercialization of LOQTORZI®, advance clinical development of other product candidates, and for general corporate purposes. The offering is expected to close around February 17, 2026, with TD Cowen, Guggenheim Securities, and Oppenheimer & Co. acting as joint bookrunners.
Coherus Oncology, Inc. Announces Pricing of Public Offering of Common Stock
Coherus Oncology, Inc. announced the pricing of an underwritten public offering of 28,600,000 shares of its common stock at $1.75 per share, expecting gross proceeds of approximately $50.1 million. The company plans to use the net proceeds for the commercialization of LOQTORZI®, clinical development of product candidates, and general corporate purposes. The offering is anticipated to close around February 17, 2026, with TD Cowen, Guggenheim Securities, and Oppenheimer & Co. acting as joint bookrunners.
Coherus plans stock sale to fund LOQTORZI commercialization
Coherus Oncology (NASDAQ: CHRS) announced a proposed underwritten public offering of its common stock to fund the commercialization of LOQTORZI (toripalimab-tpzi), continue clinical development of product candidates, and for general corporate purposes. This offering includes a 30-day option for underwriters to purchase up to 15% additional shares and is subject to market conditions. Following the news, Coherus' stock declined by 15.92%, reflecting investor concern over potential dilution.
Analysts’ Top Healthcare Picks: Coherus Biosciences (CHRS), Pfizer (PFE)
Two healthcare companies, Coherus Biosciences (CHRS) and Pfizer (PFE), have received bullish analyst ratings. H.C. Wainwright reiterated a Buy rating for Coherus Biosciences with a $7.00 price target, while Oppenheimer initiated coverage with a Buy rating and a $10.00 price target. CMB International Securities maintained a Buy rating on Pfizer with a $35.46 price target, and TipRanks – DeepSeek upgraded the stock to Buy with a $29.00 price target.
Oppenheimer initiates Coherus Biosciences stock with Outperform rating
Oppenheimer has initiated coverage on Coherus Biosciences (NASDAQ:CHRS) with an Outperform rating and a $10.00 price target, suggesting a significant upside of 529%. The firm highlighted the oncology company's strong pipeline, including its lead anti-CCR8 antibody tagmokitug and anti-IL-27 antibody casdozokitug, along with an existing approved PD-1 backbone. Coherus is also noted for its low revenue valuation multiple despite being profitable with a P/E ratio of 3.02.
Coherus Oncology Surges 30% Following Oppenheimer’s Outperform Rating
Coherus Oncology Inc. (CHRS) saw its stock surge by over 20% following an "Outperform" rating from Oppenheimer, which set a $10 price target. Despite this positive catalyst and promising results for its investigational anti-CCR8 antibody, the company faces significant financial hurdles, including negative margins and declining revenue. Investors are advised to exercise cautious optimism, balancing the potential of the therapeutic pipeline against current financial instabilities.
Coherus BioSciences Shares Surge on Analyst Initiation and Capital Move
Shares of Coherus BioSciences surged following an "Outperform" rating initiation by Oppenheimer & Co. with a $10 price target, driven by anticipated 2026 clinical data readouts. Concurrently, the biopharmaceutical firm filed a prospectus to potentially raise up to $64.9 million, aiming to strengthen its liquidity. The sustainability of this rally will depend on forthcoming clinical trial results and the strategic deployment of the capital raise.
Coherus BioSciences Shares Surge on Analyst Initiation and Capital Move
Coherus BioSciences experienced a significant share surge following Oppenheimer's "Outperform" rating and the company's filing for a potential equity offering of up to $64.9 million. The rally is driven by anticipated clinical data readouts in 2026 for its drug candidates, tagmokitug and Loqtorzi, and the company's strategic move to capitalize on positive market sentiment. The sustainability of this momentum will depend on upcoming clinical trial results and the effective use of the raised capital.
Coherus Oncology Stock Surges Following Analyst Ratings and Clinical Developments
Coherus Oncology Inc. (CHRS) stock surged by 20.75% amidst positive analyst ratings and promising clinical advancements, particularly for its anti-CCR8 monoclonal antibody, Tagmokitug. Despite facing significant financial challenges and negative profitability ratios, an "Outperform" rating from Oppenheimer with a $10 price target has driven optimistic investor sentiment. Traders are cautiously watching for continued bullish movement, with potential entry points and resistance levels identified, while balancing enthusiasm with the company's fiscal realities.
Coherus Oncology files prospectus to offer up to $64.9 million in stock
Coherus Oncology has filed a prospectus supplement to offer up to $64.9 million worth of common stock through its existing Sales Agreement with TD Cowen. The company's innovative cancer treatment, tagmokitug, has shown promising results in research, as well as positive analyst coverage from Oppenheimer. Recent leadership changes include Jean-Frédéric Viret as the new CFO of SpyGlass Pharma, previously of Coherus BioSciences.
Oppenheimer Initiates Coherus Oncology (CHRS) at Outperform with $10 Price Target
Oppenheimer has initiated coverage of Coherus Oncology (CHRS) with an Outperform rating and a $10 price target, highlighting the significant potential of its anti-CCR8 monoclonal antibody, tagmokitug, for various cancers. Following this rating, Coherus shares saw a substantial rise of approximately 31%. The company's lead product, Loqtorizi, and its other pipeline candidates, including casdozokitug, are expected to drive future growth and market competitiveness.
Coherus Oncology files prospectus to offer up to $64.9 million in stock
Coherus Oncology announced it has filed a prospectus supplement to offer up to $64.9 million in common stock through its existing Sales Agreement with TD Cowen. The company's common stock is listed on The Nasdaq Global Market. This filing follows recent positive developments for Coherus BioSciences, including promising research on its investigational cancer treatment and new analyst coverage.
Oppenheimer Initiates Coverage on Coherus BioSciences With Outperform Rating
Oppenheimer has initiated coverage on Coherus BioSciences (now Coherus Oncology, Inc.) with an "Outperform" rating. This news highlights the company's focus on immunotherapies for cancer, including products like LOQTORZI and UDENYCA, and its robust pipeline. The report mentions recent activities such as presentations at major healthcare conferences and various financial and clinical updates.
Biotech Stocks Surge: Coherus Up 9.09% in After-Hours Trading
Coherus Oncology (CHRS) saw a 9.09% increase in after-hours trading, closing at $1.73, indicating strong investor confidence. Other biotech firms like Sensei Biotherapeutics (SNSE) and uniQure N.V. (QURE) also experienced significant surges in after-hours trading, reflecting positive market expectations for the sector. Wall Street analysts forecast a bullish outlook for CHRS, with an average one-year price target of $5.50.
Coherus publishes data on tagmokitug antibody for cancer treatment By Investing.com
Coherus Oncology announced the publication of research data for its investigational anti-CCR8 monoclonal antibody, tagmokitug, demonstrating its selective ability to eliminate CCR8+ T regulatory cells in solid tumors. The drug is currently in Phase 1b/2a clinical trials and is part of Coherus's broader immunotherapy pipeline. This follows recent positive long-term survival data for their cancer drug LOQTORZI and new biomarker data for CHS-114.
Coherus Management to Present at the 44th Annual J.P. Morgan Healthcare Conference
Coherus Oncology, Inc. announced that its senior management will present at the 44th Annual J.P. Morgan Healthcare Conference on January 13, 2026, at 10:30 a.m. Pacific Time. The presentation and Q&A session will be accessible via webcast on the Coherus website, with a replay available until February 13, 2026. The company will discuss its commercial-stage PD-1 inhibitor, LOQTORZI, and its pipeline of oncology candidates.
Coherus publishes data on tagmokitug antibody for cancer treatment By Investing.com
Coherus Oncology, Inc. announced comprehensive research data on its investigational anti-CCR8 monoclonal antibody, tagmokitug, published in Molecular Cancer Therapeutics. The data showcases tagmokitug's picomolar binding affinity and selective elimination of CCR8+ T regulatory cells, with promising anti-tumor activity in preclinical models and early clinical trials. Coherus is evaluating tagmokitug in Phase 1b/2a clinical trials for solid tumors, expanding its immunotherapy pipeline alongside approved drugs like LOQTORZI.
Coherus Oncology Announces Publication in Molecular Cancer
Coherus Oncology announced the publication of preclinical and clinical biomarker research for its investigational anti-CCR8 monoclonal antibody, tagmokitug, in Molecular Cancer Therapeutics. The publication highlights tagmokitug's strong pharmacology, picomolar affinity for CCR8 without off-target binding, and its selective elimination of CCR8+ T regulatory cells. These findings support the ongoing advancement of tagmokitug in clinical studies for various solid tumors.
Coherus Oncology (NASDAQ:CHRS) Stock Price Crosses Above 200 Day Moving Average - Time to Sell?
Coherus Oncology (NASDAQ:CHRS) stock has crossed above its 200-day moving average, trading at $1.39. Analysts have a "Hold" consensus rating with an average target price of $4.02, reflecting mixed opinions. The company, with a market cap of approximately $168 million, slightly beat EPS estimates but missed revenue in its last quarterly report.
Coherus BioSciences stock jumps after positive cancer drug survival data
Coherus BioSciences Inc (NASDAQ:CHRS) stock surged 8.2% after reporting positive long-term survival data for its cancer drug LOQTORZI. The drug, used for nasopharyngeal carcinoma, demonstrated a median survival of 64.8 months when combined with chemotherapy, significantly outperforming chemotherapy alone. This data reinforces LOQTORZI's potential as a standard of care and has received FDA approval for specific NPC treatments.
Coherus Announces Six-Year JUPITER-02 Follow-up Results Showing LOQTORZI® plus Chemotherapy Nearly Doubles Median Overall Survival in Nasopharyngeal Carcinoma
Coherus Oncology, Inc. announced six-year overall survival (OS) follow-up results from the Phase 3 JUPITER-02 trial, demonstrating that LOQTORZI® plus chemotherapy nearly doubled the median overall survival in recurrent or metastatic nasopharyngeal carcinoma (RM-NPC) patients to 64.8 months, compared to 33.7 months with chemotherapy alone. These findings, presented at ESMO Asia 2025, reinforce LOQTORZI's role in improving outcomes for RM-NPC patients, highlighting a significant and durable survival advantage. The company emphasizes the urgent clinical need to incorporate LOQTORZI as a first-line treatment due to its potential for meaningful clinical benefit and increased long-term survival.
Coherus BioSciences stock jumps after positive cancer drug survival data
Coherus BioSciences Inc. (NASDAQ:CHRS) stock rose over 8% after reporting significant long-term survival data for its cancer drug LOQTORZI. Patients receiving LOQTORZI plus chemotherapy for nasopharyngeal carcinoma showed a median survival of 64.8 months, nearly double that of chemotherapy alone. This data suggests LOQTORZI could become a standard of care for this aggressive cancer.
Earnings call transcript: Coherus BioSciences Q3 2025 revenue falls short
Coherus BioSciences reported a Q3 2025 EPS miss at -0.33 USD against a forecast of -0.32 USD, with revenue falling short at 11.6 million USD compared to an expected 13.36 million USD. Despite a 92% YoY increase in LOQTORZI net revenue and strategic divestments, the company's stock declined by 4.79%. Coherus aims for future growth by expanding its sales force and focusing on its oncology pipeline, with key clinical data readouts anticipated in 2026.
Revenues Working Against Coherus Oncology, Inc.'s (NASDAQ:CHRS) Share Price Following 26% Dive
Coherus Oncology, Inc. (NASDAQ:CHRS) has seen its share price drop by 26% over the last 30 days, despite a 63% gain over the past year. The company's low price-to-sales (P/S) ratio of 0.5x, significantly below the industry average, is largely attributed to analyst forecasts predicting a 15% annual revenue contraction for the next three years, contrasting with an expected 129% industry growth. This suggests that while previous revenue growth was strong, the market is discounting the stock due to concerns over future revenue performance.
Coherus Oncology: Five Readouts Or More Possible In 2026
Coherus Oncology's Loqtorzi revenue has shown significant growth in Q2 2025, reaching $10M. The company anticipates five or more drug readouts in 2026, including for casdozokitug in hepatocellular carcinoma and CHS-114 across various cancers like gastric, head and neck, esophageal squamous cell, and colorectal. These upcoming readouts suggest potential advancements in their developmental pipeline for the biotech firm.
Coherus Biosciences Regains Nasdaq Compliance
Coherus Biosciences (CHRS) has regained compliance with Nasdaq's listing requirements after its stock price fell below $1.00 per share. Despite an analyst Buy rating with a $4.00 price target, TipRanks' AI Analyst, Spark, assesses CHRS as Neutral due to significant financial challenges and competitive pressures. The company, which operates in oncology treatments and biosimilar products, faces declining revenue and negative cash flows.
Maxim Group upgrades Coherus Biosciences stock to Buy on oncology pivot
Maxim Group has upgraded Coherus Biosciences (NASDAQ:CHRS) from Hold to Buy with a $4.00 price target, citing the company's successful pivot from biosimilars to immuno-oncology. Coherus's strong pipeline of novel oncology treatments, including CHS-114 and casdozokitug, alongside the market share gains of its Loqtorzi treatment, are key drivers for the upgrade. The company's financial health has also significantly improved following the divestiture of its biosimilar Udenyca.
Biotech Leader Coherus Oncology Sets Major Conference Schedule: Baird, Wainwright, and UBS Events
Coherus Oncology (NASDAQ: CHRS) announced its participation in three investor conferences in Fall 2025: the Baird 2025 Global Healthcare Conference, the H.C. Wainwright Global Investment Conference, and the UBS Virtual Oncology Day. The presentations will be accessible via webcasts on the company's investor relations website, with replays available for 30 days. Investors seeking one-on-one meetings with management are advised to contact their bank representatives.
Earnings call transcript: Coherus BioSciences Q2 2025 misses EPS, stock dips
Coherus BioSciences (CHRS) reported a Q2 2025 EPS miss of -$0.34 against an expected -$0.26, causing a 3.49% stock dip in after-hours trading despite a slight revenue beat. The company highlighted strong Loktorzi revenue growth and a solid cash position, aiming for ex-US licensing deals and collaborations to expand its oncology pipeline through 2026. Management expressed confidence in future growth through commercial execution and pipeline catalysts.
Intas and Accord BioPharma Acquire Coherus BioSciences’ UDENYCA
Intas Pharmaceuticals, through its Accord brand subsidiaries, has acquired UDENYCA (pegfilgrastim-cbqv) from Coherus BioSciences, Inc., making it a major global supplier of pegfilgrastim biosimilar. This acquisition significantly expands Intas and Accord’s FDA-approved biosimilar portfolio and strengthens their position in the global biosimilar market. Accord BioPharma will continue the commercialization of UDENYCA, which offers three patient-friendly administration options.
Pegfilgrastim Biosimilars Market to Reach USD 3.39 Billion by 2032, Expanding at a CAGR of 9.1% | Coherent Market Insights
The global pegfilgrastim biosimilars market is projected to grow from USD 1.84 billion in 2025 to USD 3.39 billion by 2032, driven by a compound annual growth rate of 9.1%, according to Coherent Market Insights. This expansion is attributed to the increasing demand for affordable alternatives to expensive biologic drugs, the rising prevalence of cancer, and supportive regulatory initiatives. Key trends include innovation in delivery systems, personalized medicine, the development of long-acting biosimilars, and expansion into emerging markets.
Coherus Makes Bold Strategic Shift: Rebrands as Cancer-Focused Powerhouse with 3 Novel Immunotherapies
Coherus BioSciences has rebranded as Coherus Oncology, signaling its exclusive focus on innovative cancer immunotherapy treatments. The company is advancing a pipeline centered around the FDA-approved PD-1 inhibitor LOQTORZI®, along with promising candidates CHS-114 and casdozokitug. This strategic shift aims to unlock immune resistance and develop next-generation combination therapies for various cancers, supported by a world-class team and Scientific Advisory Board.
Coherus Completes Strategic Transformation to Coherus Oncology, Focusing Exclusively on Innovative Cancer Therapeutics
Coherus BioSciences Inc. has changed its name to Coherus Oncology, Inc. to better reflect its exclusive focus on innovative cancer therapeutics. The company, which is developing a portfolio of novel combination therapies including LOQTORZI® (toripalimab-tpzi), CHS-114, and casdozokitug, aims to become a significant player in the immuno-oncology space. This strategic transformation emphasizes their commitment to extending cancer patients' survival and improving their quality of life with next-generation therapies.
Coherus BioSciences’ SWOT analysis: promising pipeline faces clinical hurdles
Coherus BioSciences is making strides in biosimilar drugs and oncology therapeutics with promising early-stage clinical data for CHS-114/toripalimab and casdozo. While the company demonstrates operational efficiency with a solid gross profit margin, it faces challenges including clinical development risks and intense competition. Its future hinges on the successful translation of early trial data into late-stage success, particularly for treatments overcoming PD-1 resistance and liver cancer.
Coherus BioSciences, Inc.'s (NASDAQ:CHRS) 32% Dip In Price Shows Sentiment Is Matching Revenues
Coherus BioSciences (NASDAQ:CHRS) has seen its share price drop 32% in the last month, contributing to a 64% decline over the past year. The company's price-to-sales (P/S) ratio of 0.3x is significantly lower than the industry average, reflecting investor concerns over its poor revenue growth and forecasts of a 24% annual decline in revenue over the next three years. This poor outlook on revenue growth is driving the low P/S ratio, indicating market sentiment aligns with its financial performance.
Coherus BioSciences Reports First Quarter 2025 Financial Results and Provides Business Update
Coherus BioSciences reported its Q1 2025 financial results, highlighting the completion of its strategic transformation to innovative oncology after the UDENYCA divestiture. The company generated $7.3 million in LOQTORZI net revenue and presented positive Phase 1b data for CHS-114, an anti-CCR8 antibody, at the 2025 AACR Annual Meeting. Coherus posted a net loss from continuing operations of $47.4 million, or $(0.41) per share, focusing on advancing its oncology pipeline.
Coherus loses commercial chief amid exit from biosimilar space
Coherus BioSciences' chief commercial officer, Paul Reider, has resigned as the company completes its strategic shift from biosimilars to novel immuno-oncology programs. Reider's departure follows Coherus' sale of its last biosimilar product, Udenyca, to Intas Pharmaceuticals, and is part of a broader company restructuring aimed at reducing headcount and focusing on its anti-PD-1 antibody, Loqtorzi. The company is now concentrating its commercial efforts on Loqtorzi sales and educating clinicians on its use.
Watkins Assists Coherus BioSciences in Obtaining CFIUS Clearance
Latham & Watkins LLP represented Coherus BioSciences, Inc. in obtaining clearance from the Committee on Foreign Investment in the United States (CFIUS). The CFIUS concluded that there were no national security issues related to Coherus' divestiture of its UDENYCA franchise to Intas Pharmaceuticals. The transaction team included lawyers from both CFIUS and M&A practices.
Intas Pharmaceuticals Acquires UDENYCA Business from Coherus BioSciences
Intas Pharmaceuticals, through its U.S. specialty division Accord BioPharma, has completed the acquisition of the UDENYCA (pegfilgrastim-cbqv) business from Coherus BioSciences Inc. This acquisition expands Accord BioPharma's portfolio of FDA-approved biosimilar products and integrates key Coherus employees to ensure continuity and growth. The move reinforces Intas' commitment to improving patient access to high-quality treatments in the biosimilar space.
Accord BioPharma, Inc. Announces Completion of UDENYCA® (pegfilgrastim-cbqv) Franchise Acquisition from Coherus BioSciences, Inc., Expanding U.S. Biosimilar Portfolio
Accord BioPharma, Inc., the U.S. specialty division of Intas Pharmaceuticals, has completed its acquisition of the UDENYCA® (pegfilgrastim-cbqv) business from Coherus BioSciences, Inc. This acquisition expands Accord BioPharma's portfolio of FDA-approved biosimilar products and strengthens its presence in the U.S. market. The deal includes the transfer of key Coherus employees to Accord BioPharma, ensuring continuity and expertise for the UDENYCA franchise.
Coherus Completes Strategic Transformation with Successful Divestiture of UDENYCA® Franchise
Coherus BioSciences, Inc. announced the completion of its divestiture of the UDENYCA franchise to Intas Pharmaceuticals Ltd. for a deal valued at up to $558.4 million. This strategic move provides Coherus with a $250 million post-close cash balance, extending its cash runway into 2027, and allows the company to focus exclusively on its innovative novel oncology programs, including LOQTORZI, Casdozokitug, and CHS-114. Coherus is now positioned as a revenue-generating oncology company with a strong balance sheet and a promising mid-stage pipeline.
Coherus BioSciences, Inc. SEC 10-K Report
Coherus BioSciences, Inc. has released its annual 10-K report, detailing a return to profitability with a net income of $28.51 million, driven by strategic divestitures and successful product launches like LOQTORZI. The company is refocusing on its immuno-oncology pipeline, particularly LOQTORZI, following the sale of its UDENYCA business, and is actively managing its capital to strengthen its financial position. Despite these strategic moves, Coherus faces significant risks including profitability challenges, intense market competition, regulatory scrutiny, and operational dependencies.
